Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

TNXP

Tonix Pharmaceuticals Holding Corp

May 17 • 04:00PM ET

0.1972

Dollar change +0.0156
Percentage change 8.59	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.55	Insider Own	0.01%	Shs Outstand	95.54M	Perf Week	14.85%
Market Cap	18.84M	Forward P/E	-	EPS next Y	-0.60	Insider Trans	0.00%	Shs Float	95.54M	Perf Month	25.61%
Income	-98.59M	PEG	-	EPS next Q	-0.26	Inst Own	15.02%	Short Float	1.67%	Perf Quarter	-48.31%
Sales	10.25M	P/S	1.84	EPS this Y	-11.05%	Inst Trans	14.29%	Short Ratio	0.65	Perf Half Y	-58.13%
Book/sh	1.47	P/B	0.13	EPS next Y	37.17%	ROA	-62.71%	Short Interest	1.60M	Perf Year	-89.57%
Cash/sh	0.07	P/C	2.67	EPS next 5Y	-	ROE	-72.08%	52W Range	0.12 - 2.13	Perf YTD	-51.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	79.31%	ROI	-85.83%	52W High	-90.72%	Beta	2.19
Dividend TTM	-	Quick Ratio	0.87	Sales past 5Y	0.00%	Gross Margin	-7.12%	52W Low	64.06%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	1.47	EPS Y/Y TTM	70.31%	Oper. Margin	-1032.48%	RSI (14)	54.05	Volatility	5.84% 7.25%
Employees	103	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-961.87%	Recom	1.00	Target Price	2.97
Option/Short	No / Yes	LT Debt/Eq	0.06	EPS Q/Q	94.33%	Payout	-	Rel Volume	2.90	Prev Close	0.18
Sales Surprise	-35.53%	EPS Surprise	34.55%	Sales Q/Q	-	Earnings	May 13 AMC	Avg Volume	2.44M	Price	0.20
SMA20	13.15%	SMA50	-12.33%	SMA200	-58.93%	Trades		Volume	7,082,041	Change	8.59%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-18-22	Initiated	Noble Capital Markets	Outperform
Apr-18-19	Upgrade	ROTH Capital	Neutral → Buy	$4
Aug-18-17	Upgrade	ROTH Capital	Neutral → Buy	$6
Sep-07-16	Downgrade	ROTH Capital	Buy → Neutral
Feb-17-16	Reiterated	Oppenheimer	Outperform	$18 → $10
Nov-04-15	Initiated	Cantor Fitzgerald	Buy
Jun-12-15	Initiated	Oppenheimer	Outperform	$18
Feb-17-15	Reiterated	ROTH Capital	Buy	$10 → $12
Sep-29-14	Reiterated	ROTH Capital	Buy	$17 → $10

May-15-24 08:00AM	Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase (GlobeNewswire)
May-13-24 04:30PM	Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE) +6.53%
Apr-24-24 08:00AM	Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase (GlobeNewswire)
Apr-09-24 06:31AM	3 Biotech Stocks to Dump Before They Go to Zero (InvestorPlace)
04:15PM	Loading…
Apr-01-24 04:15PM	Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
Mar-28-24 09:32AM	Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering (GlobeNewswire) -43.10%
Mar-25-24 08:00AM	Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome (GlobeNewswire) -5.20%
Mar-24-24 04:05PM	3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million (InvestorPlace)
Mar-21-24 08:00AM	Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting (GlobeNewswire)
Mar-20-24 08:00AM	Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya for the Management of Fibromyalgia (GlobeNewswire)
Mar-19-24 08:00AM	Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024 (GlobeNewswire)
Mar-12-24 08:00AM	Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring (GlobeNewswire) -8.86%
Mar-11-24 08:00AM	Tonix Pharmaceuticals Reports Improvement in Brain Fog, in Fibromyalgia Patients Treated with Tonmya in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia (GlobeNewswire)
Mar-07-24 09:37AM	New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT (GlobeNewswire)
08:00AM	Loading…
08:00AM	Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy (GlobeNewswire)
Mar-06-24 08:00AM	Tonix Pharmaceuticals Selects EVERSANA to Support Launch Strategy and Commercialization Planning of Tonmya for the Management of Fibromyalgia (GlobeNewswire)
Mar-05-24 08:00AM	Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans (GlobeNewswire)
Feb-29-24 08:00AM	Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia (GlobeNewswire)
Feb-28-24 08:00AM	Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers (GlobeNewswire)
06:56AM	Tonix Pharmaceuticals drug TNX-102 SL gets FDA ok for US Department of Defense funded trial (News Direct)
06:54AM	Tonix Pharmaceuticals' Fibromyalgia Trial Shows Promising Results in Webinar Presentation (News Direct)
Feb-27-24 08:00AM	Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya to Support Development and Partnering in Japan and China (GlobeNewswire) +6.88%
Feb-26-24 08:00AM	New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain (ACCESSWIRE) +6.93%
Feb-25-24 02:12PM	3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond (InvestorPlace)
Feb-23-24 09:30AM	New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series (GlobeNewswire)
Feb-20-24 08:00AM	Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference (GlobeNewswire)
Feb-16-24 09:30AM	New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT (GlobeNewswire)
Feb-15-24 08:45AM	Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032 (GlobeNewswire)
08:00AM	Tonix Drug Shown To Relieve Pain in Fibromyalgia Without Risk of Addiction (ACCESSWIRE)
08:00AM	Loading…
Feb-14-24 08:00AM	Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya , Plans to File NDA for FDA Approval in Second Half of 2024 (GlobeNewswire) +9.35%
Feb-13-24 08:00AM	Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya for the Management of Fibromyalgia (GlobeNewswire)
Feb-12-24 08:00AM	Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD (GlobeNewswire) +12.12%
Feb-01-24 08:00AM	New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval (ACCESSWIRE) +7.50%
Jan-31-24 07:00AM	Tonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVID (GlobeNewswire)
Jan-30-24 05:00PM	20 Countries With The Highest Number of Drug Trafficking in the World (Insider Monkey)
Jan-29-24 07:00AM	Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Trade Name for TNX-102 SL for the Management of Fibromyalgia (GlobeNewswire)
Jan-26-24 05:31PM	Best Drug and Alcohol Rehab Centers in Each of 30 Biggest Cities in the US (Insider Monkey)
Jan-25-24 07:00AM	Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P. (GlobeNewswire) +9.57%
Jan-24-24 03:28PM	Tonix Study Reveals Promising Fibromyalgia Treatment (Exec Edge)
Jan-09-24 07:00AM	Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia (GlobeNewswire) -10.17%
Jan-03-24 07:00AM	Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 Trial (GlobeNewswire) -6.13%
Jan-02-24 06:08AM	Tonix Pharmaceuticals announces key topline data from 2nd Phase 3 Clinical Trial of TNX-102 SL (News Direct)
Dec-20-23 10:35AM	Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 Million (GlobeNewswire) -36.78%
10:30AM	Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia (GlobeNewswire)
Dec-14-23 09:15AM	Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL (ACCESSWIRE) +22.74%
Dec-12-23 01:40PM	Tonix Pharmaceuticals shared details of IND clearance for Phase 2 trial of TNX-2900 (News Direct)
Dec-11-23 07:00AM	Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public Meeting (GlobeNewswire)
Dec-04-23 07:00AM	Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity (GlobeNewswire) -10.38%
Nov-28-23 07:00AM	Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December (GlobeNewswire)
Nov-20-23 01:57PM	Tonix Pharmaceuticals' CEO reveals next-generation COVID vaccine technology chosen for key program (News Direct)
01:53PM	Tonix Pharmaceuticals finish Phase 3 trial of TNX-102 SL for management of Fibromyalgia (News Direct)
Nov-15-23 07:00AM	Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia (GlobeNewswire)
Nov-13-23 07:00AM	Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder (GlobeNewswire)
Nov-09-23 04:15PM	Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Nov-02-23 08:00AM	Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials (GlobeNewswire)
Oct-31-23 05:00PM	Tonix Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder (GlobeNewswire)
Oct-30-23 07:00AM	Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress (GlobeNewswire)
Oct-26-23 07:00AM	Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs (GlobeNewswire)
Oct-25-23 08:45AM	New Hope for Long COVID Sufferers (ACCESSWIRE)
Oct-19-23 07:00AM	Tonix Pharmaceuticals Presents Data from its Horsepox-Based Vaccine Development Platform at the World Vaccine Congress Europe (GlobeNewswire)
Oct-18-23 07:00AM	Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models (GlobeNewswire)
Oct-16-23 07:00AM	Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder (GlobeNewswire)
Oct-12-23 07:00AM	Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference (GlobeNewswire)
Oct-11-23 07:00AM	Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe (GlobeNewswire)
Oct-09-23 07:00AM	Tonix Pharmaceuticals Provides Overview of TNX-2900 Program for the Treatment of Prader-Willi Syndrome at the Foundation for Prader-Willi Research Family Conference (GlobeNewswire)
Oct-04-23 07:00AM	Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain (GlobeNewswire) +6.72%
Sep-28-23 09:00PM	Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering (GlobeNewswire) -5.26%
04:01PM	Tonix Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Sep-27-23 08:30AM	Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder (GlobeNewswire) -6.67%
Sep-26-23 10:18AM	TNXP: Encouraging Topline Results for Long COVID Trial (Zacks)
Sep-21-23 07:00AM	Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023 (GlobeNewswire) -7.21%
Sep-19-23 01:54PM	Tonix Pharmaceuticals releases positive results from Proof-Of-Concept Study on TNX-102 SL (News Direct)
Sep-18-23 07:00AM	Tonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congress (GlobeNewswire) -6.50%
Sep-15-23 09:30AM	New to The Street Announces Episodes 510 and 511 Six Corporate Interviews, airings on Newsmax and FOX Business Network, Broadcastings Begin Saturday, September 16, 2023, at 3:30 PM ET (GlobeNewswire)
Sep-14-23 07:00AM	Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023 (GlobeNewswire)
Sep-06-23 07:00AM	Tonix Pharmaceuticals Announces Commitment to Supply Tosymra® (sumatriptan Nasal Spray) 10 mg for Treatment of Acute Migraine to Meet Potential Increased Demand Following GSKs Planned Discontinuation of Imitrex® (sumatriptan) Nasal Spray After January 2024 (GlobeNewswire)
Sep-05-23 07:32AM	UPDATE 1-Tonix's long COVID drug fails to meet mid-stage trial goal (Reuters) -8.50%
07:05AM	Tonix's long COVID drug fails to meet mid-stage trial goal (Reuters)
07:00AM	Tonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID (GlobeNewswire)
Aug-28-23 01:13PM	Tonix Pharmaceuticals begins Phase 1 trial of TNX-1500 in healthy participants (News Direct)
Aug-21-23 01:18PM	Tonix Pharmaceuticals begins Phase 1 trial of TNX-1500 in healthy participants (News Direct)
07:00AM	Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox (GlobeNewswire)
Aug-17-23 07:00AM	Tonix Pharmaceuticals to Present at the August Virtual Investor Summit (GlobeNewswire)
Aug-16-23 07:00AM	Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers (GlobeNewswire)
Aug-10-23 04:30PM	Tonix Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Aug-07-23 07:00AM	Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID (GlobeNewswire)
Aug-01-23 04:01PM	Tonix Pharmaceuticals Announces Closing of $7 Million Public Offering (GlobeNewswire)
07:00AM	Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia (GlobeNewswire)
Jul-31-23 07:00AM	Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 STROBE Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder (GlobeNewswire)
Jul-27-23 09:31PM	Tonix Pharmaceuticals Announces Pricing of $7 Million Public Offering (GlobeNewswire)
04:01PM	Tonix Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Jul-26-23 04:05PM	Tonix Pharmaceuticals Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023 (GlobeNewswire)
Jul-24-23 07:00AM	Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test (GlobeNewswire)
Jul-17-23 07:00AM	Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder (GlobeNewswire)
Jul-10-23 07:00AM	Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 POWER Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity (GlobeNewswire) +7.50%
Jul-06-23 08:09AM	TNXP: Acquires Two Commercial Products for Migraine Treatment (Zacks Small Cap Research) -5.49%
07:00AM	Tonix Pharmaceuticals Comments on Two Long COVID Conferences Sponsored by the U.S. National Academies (GlobeNewswire)
Jul-03-23 07:00AM	Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products (GlobeNewswire)
Jun-28-23 03:21PM	Tonix Pharmaceuticals fibromyalgia study published in American College of Rheumatology (News Direct) +5.67%

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TNXP

Tonix Pharmaceuticals Holding Corp

Upgrade your FINVIZ experience